Paul K. Stockman

3.0k total citations · 1 hit paper
39 papers, 1.9k citations indexed

About

Paul K. Stockman is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Paul K. Stockman has authored 39 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Pulmonary and Respiratory Medicine and 15 papers in Oncology. Recurrent topics in Paul K. Stockman's work include Cancer Immunotherapy and Biomarkers (8 papers), Acute Myeloid Leukemia Research (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Paul K. Stockman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Acute Myeloid Leukemia Research (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Paul K. Stockman collaborates with scholars based in United Kingdom, United States and France. Paul K. Stockman's co-authors include John D. Hayes, Geoffrey J. Beckett, Malcolm Ranson, Ronald B. Natale, Naiyer A. Rizvi, Paul Germonpré, Ramaswamy Govindan, Sarah J. Kennedy, David Bodkin and Bethany Sleckman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Paul K. Stockman

39 papers receiving 1.8k citations

Hit Papers

Tremelimumab as second-line or third-line treatment in re... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
    2017 304 citations Michele Maio, Arnaud Scherpereel et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul K. Stockman United Kingdom 21 935 807 737 323 146 39 1.9k
Howard Fingert United States 23 1.1k 1.1× 765 0.9× 220 0.3× 701 2.2× 209 1.4× 47 1.9k
Amrita Desai United States 19 1.3k 1.4× 657 0.8× 1.1k 1.5× 147 0.5× 359 2.5× 36 2.3k
Kim Chi Canada 20 636 0.7× 872 1.1× 799 1.1× 94 0.3× 520 3.6× 49 1.9k
Soji Kakiuchi Japan 21 850 0.9× 998 1.2× 910 1.2× 83 0.3× 313 2.1× 41 1.9k
Gregory Friberg United States 18 722 0.8× 504 0.6× 318 0.4× 91 0.3× 269 1.8× 35 1.2k
Kazuki Yamanaka Japan 23 487 0.5× 756 0.9× 512 0.7× 116 0.4× 335 2.3× 65 1.6k
Diana C. Birle Canada 12 621 0.7× 1.2k 1.5× 395 0.5× 60 0.2× 347 2.4× 12 1.8k
Maja J.A. de Jonge Netherlands 19 848 0.9× 865 1.1× 420 0.6× 61 0.2× 259 1.8× 40 1.6k
Luigi Formisano Italy 25 1.1k 1.2× 1.1k 1.4× 772 1.0× 107 0.3× 494 3.4× 73 2.2k
Jeff Sosman United States 20 1.2k 1.3× 1.2k 1.4× 301 0.4× 101 0.3× 278 1.9× 38 2.2k

Countries citing papers authored by Paul K. Stockman

Since Specialization
Citations

This map shows the geographic impact of Paul K. Stockman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul K. Stockman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul K. Stockman more than expected).

Fields of papers citing papers by Paul K. Stockman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul K. Stockman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul K. Stockman. The network helps show where Paul K. Stockman may publish in the future.

Co-authorship network of co-authors of Paul K. Stockman

This figure shows the co-authorship network connecting the top 25 collaborators of Paul K. Stockman. A scholar is included among the top collaborators of Paul K. Stockman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul K. Stockman. Paul K. Stockman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Planchard, David, Niels Reinmuth, С. В. Орлов, et al.. (2020). ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Annals of Oncology. 31(5). 609–618. 118 indexed citations
2.
Baverel, Paul, Lorin Roskos, Nancy Lee, et al.. (2019). Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status. Clinical and Translational Science. 12(5). 450–458. 16 indexed citations
3.
Chapman, Elinor, Melanie Oates, Barry R. Davies, et al.. (2017). Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia. Oncotarget. 8(61). 102948–102964. 8 indexed citations
4.
Maio, Michele, Arnaud Scherpereel, Luana Calabrò, et al.. (2017). Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet Oncology. 18(9). 1261–1273. 304 indexed citations breakdown →
5.
6.
7.
8.
Kantarjian, Hagop M., Mikkael A. Sekeres, Vincent Ribrag, et al.. (2013). Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML. Clinical Lymphoma Myeloma & Leukemia. 13(5). 559–567. 46 indexed citations
9.
André, Fabrice, Malcolm Ranson, Emma Dean, et al.. (2013). Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .. Cancer Research. 73(8_Supplement). LB–145. 34 indexed citations
10.
11.
Schwartz, Gary K., Richard D. Carvajal, Rachel Midgley, et al.. (2012). Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Investigational New Drugs. 31(2). 370–380. 61 indexed citations
12.
13.
Boss, David S., Petronella O. Witteveen, Martijn P. Lolkema, et al.. (2010). Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Annals of Oncology. 22(2). 431–437. 85 indexed citations
14.
Natale, Ronald B., David Bodkin, Ramaswamy Govindan, et al.. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. Journal of Clinical Oncology. 27(15). 2523–2529. 194 indexed citations
15.
Cummings, Jeffrey L., Simon P. Langdon, Alison Ritchie, et al.. (1996). Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice. Annals of Oncology. 7(3). 291–296. 17 indexed citations
16.
Stockman, Paul K.. (1992). Anti-Snob Zoning in Massachusetts: Assessing One Attempt at Opening the Suburbs to Affordable Housing. Virginia Law Review. 78(2). 535–535. 9 indexed citations
17.
Hayes, John D. & Paul K. Stockman. (1989). Electrophoresis of proteins and nucleic acids: II--Techniques and applications.. BMJ. 299(6704). 907–910. 3 indexed citations
18.
Hayes, John D., Lesley I. McLellan, Paul K. Stockman, John Chalmers, & Geoffrey J. Beckett. (1987). Glutathione S-transferases in man: the relationship between rat and human enzymes. Biochemical Society Transactions. 15(4). 721–725. 25 indexed citations
19.
Hussey, A J, Paul K. Stockman, Geoffrey J. Beckett, & John D. Hayes. (1986). Variations in the glutathione S-transferase subunits expressed in human livers. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 874(1). 1–12. 53 indexed citations
20.
Stockman, Paul K., Geoffrey J. Beckett, & John D. Hayes. (1985). Identification of a basic hybrid glutathione S-transferase from human liver. Glutathione S-transferase δ is composed of two distinct subunits (B1 and B2). Biochemical Journal. 227(2). 457–465. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Howard Fingert Breakdown of academic impact, for papers by Amrita Desai Breakdown of academic impact, for papers by Kim Chi Breakdown of academic impact, for papers by Soji Kakiuchi Breakdown of academic impact, for papers by Gregory Friberg Breakdown of academic impact, for papers by Kazuki Yamanaka Breakdown of academic impact, for papers by Diana C. Birle Breakdown of academic impact, for papers by Maja J.A. de Jonge Breakdown of academic impact, for papers by Luigi Formisano Breakdown of academic impact, for papers by Jeff Sosman
Rankless by CCL
2026